This research used computer models to analyze costs for stroke patients across 16 global countries. It examined 2,268 patients eligible for both medication and surgery. The study compared using alteplase plus surgery against surgery alone to determine financial value for healthcare systems.
The main goal was to see if the extra medication was worth the cost. Results showed adding alteplase saved money and improved value overall when treatment started within 170 minutes. The chances of it being cost-effective were very clearly high if given within 140 minutes.
However, the benefit dropped as time passed. After 200 minutes, the extra medication was not cost-effective in any country. This analysis used computer models to predict costs over 15 years. It did not report safety issues or direct health outcomes like specific survival rates.
Readers should understand this study focuses on financial value, not just medical results. It suggests quick treatment is important for cost reasons. Patients should discuss timing and treatment options with their doctors carefully before making decisions about their own care.